On May 29, RemeGen rose 5.13% in regular trading, trading at HKD 83.15 per share, with trading volume of HKD 247 million. The stock was buoyed by a series of positive clinical developments and broad biotech sector strength.

On the news front, the company announced it received FDA approval to conduct a Phase II clinical trial of Telitacicept for the treatment of IgA nephropathy in the United States. This milestone follows the recent publication of Telitacicept Phase III clinical results for IgA nephropathy in the New England Journal of Medicine, reinforcing the drug's global development trajectory. The company also recently reported first patient enrollment in Phase III trials for RC148 in advanced squamous NSCLC and Phase I/IIa trials for RC288 in advanced solid tumors, signaling continued pipeline momentum.

The broader Biotechnology sector exhibited strong gains, with Innovent Bio up 11.02%, Akeso up 6.79%, 3SBIO up 7.94%, SKB Bio up 4.34%, and BeiGene up 1.31%, reflecting sector-wide positive sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)